Navega Therapeutics focuses on advancing gene therapies through the innovative use of zinc-finger and CRISPR-based technologies for epigenome regulation. These approaches allow for precise modifications at the genetic level, enabling the development of next-generation therapies that can effectively target and regulate gene expression. By harnessing the capabilities of these technologies, Navega aims to create more effective and tailored treatments for various diseases.

The company's commitment to precision in gene therapy is underscored by its emphasis on epigenome regulation, which involves modifying the way genes are expressed without altering the underlying DNA sequence. This strategy not only enhances the specificity of therapeutic interventions but also minimizes potential off-target effects, making treatments safer and more efficient. Through its innovative pipeline, Navega Therapeutics is positioned to contribute significantly to the field of gene therapy, leveraging cutting-edge science to address unmet medical needs.

United States

We have developed a patented, non-permanent gene therapy to target pain that is non-addictive, highly specific and long-lasting. So how does this work? We were inspired by nature: there are humans that have a mutation in their genome that feel no pain whatsoever. We have imitated this process by utilizing a novel gene therapy to target pain in a non-permanent way. In our proof of concept, we have demonstrated that the mice that received our therapy have an increased pain tolerance and lower pain levels. Importantly, mice are not numb and can continue feeling mechanical stimulation, such as touch.

Navega Therapeutics

Company Details